Riskpilot← Back to searchSign inGet full accessembecta Sweden AB
ABActiveOrg 5593323958Kistagången 20 BWholesale of pharmaceutical and medical goods · NACE 4646Est. 20211-4 employees
Revenue 2024
SEK 40M
-16% vs 2023
EBITDA margin
20.3%
-8% vs 2023
Equity ratio
77.5%
Financial strength
Net profit 2024
SEK 983K
-38% vs 2023
| Revenue | SEK 40M | -16% |
| EBITDA | SEK 8,1M | -8% |
| Net profit | SEK 983K | -38% |
| Total assets | SEK 45,6M | +19% |
| Equity | SEK 35,3M | +3% |
| Employees | — | — |
Legal name
embecta Sweden AB
Org number
5593323958
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
30 augusti 2021
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-09-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten externa firmatecknaren
Company purpose
Bolaget ska bedriva verksamhet inom området för import, export, marknadsföring, försäljning och distribution av medicintekniska produkter och medicinteknisk utrustning, inklusive diagnostik- utrustning och tjänster samt bedriva därmed förenlig verksamhet.
Address
Kistagången 20 B
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 31 857 | 47 442 | 40 019 |
| Staff expenses | — | — | — |
| EBITDA | 1 135 | 8 853 | 8 123 |
| Depreciation & amort. | −6 780 | −6 660 | −6 660 |
| EBIT | −5 645 | 2 193 | 1 463 |
| Net financials | −21 | −179 | −211 |
| Profit before tax | −5 665 | 2 013 | 1 252 |
| Tax | 1 167 | −417 | −269 |
| Net profit | −4 498 | 1 596 | 983 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 36 870 | 38 478 | 45 607 |
| Equity | 32 764 | 34 360 | 35 343 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 4 107 | 4 118 | 10 264 |
| Total debt | 4 107 | 4 118 | 10 264 |
EBITDA margin
20.3%
This company
15.8%
Market median
+28% vs market
20222024
Equity ratio
77.5%
This company
38.2%
Market median
+103% vs market
20222024
Return on equity
2.8%
This company
18.4%
Market median
-85% vs market
20222024
Net profit margin
2.5%
This company
8.1%
Market median
-69% vs market
20222024
Asset turnover
0.88×
This company
1.12×
Market median
+21% vs market
20222024
Debt / equity
0.29×
This company
0.62×
Market median
+53% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
AE External Signatory | External Signatory | 2024 |
BH Chief Auditor | Chief Auditor | 2025 |
CM Authorized Recipient of Service | Authorized Recipient of Service | 2022 |
| Former (1) | ||
KB External Signatory | External Signatory | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2024 | |
| Board of Directors | 2022 | |
| Former (3) | ||
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2024 | |
| Board of Directors | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of embecta Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anke Edelgard Brouwers | External Signatory | 0 companies |
| Björn Håkan Aspenblad | Chief Auditor | 0 companies |
| Kevin Boeye | External Signatory | 0 companies |
| Carl Magnus Svernlöv | Authorized Recipient of Service | 0 companies |
| Stephanie Morgan Kelly | Deputy Board Member | 0 companies |
| Michael John Piotrowski | Deputy Board Member | 0 companies |
| Jeffrey Zimmermann Mann | Board of Directors | 0 companies |
| Brian Ralph Capone | Deputy Board Member | 0 companies |
| Gary Michael DeFazio | Board of Directors | 0 companies |